Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study

Mona M. Almramhi, Chris Finan, Catherine S. Storm, View ORCID ProfileAmand F. Schmidt, Demis A. Kia, Rachel Coneys, Sandesh Chopade, Aroon D. Hingorani, Nicholas W. Wood
doi: https://doi.org/10.1101/2022.08.01.22277781
Mona M. Almramhi
1Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom
2Faculty of Applied Medical Sciences, King Abdulaziz University, Kingdom of Saudi Arabia
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: n.wood{at}ucl.ac.uk m.almramhi{at}ucl.ac.uk mmalmaramhi{at}kau.edu.sa
Chris Finan
3Institute of Cardiovascular Science, Faculty of Population Health, University College London, London, United Kingdom
4British Heart Foundation University College London Research Accelerator, London, United Kingdom
5Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, the Netherlands
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine S. Storm
1Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom
BSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amand F. Schmidt
3Institute of Cardiovascular Science, Faculty of Population Health, University College London, London, United Kingdom
4British Heart Foundation University College London Research Accelerator, London, United Kingdom
5Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, the Netherlands
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Amand F. Schmidt
Demis A. Kia
1Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Coneys
6Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom
BSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandesh Chopade
3Institute of Cardiovascular Science, Faculty of Population Health, University College London, London, United Kingdom
4British Heart Foundation University College London Research Accelerator, London, United Kingdom
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aroon D. Hingorani
3Institute of Cardiovascular Science, Faculty of Population Health, University College London, London, United Kingdom
4British Heart Foundation University College London Research Accelerator, London, United Kingdom
7Health Data Research UK London, University College London
PhD, FRCP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas W. Wood
1Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom
PhD, FRCP, FMedSci
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: n.wood{at}ucl.ac.uk m.almramhi{at}ucl.ac.uk mmalmaramhi{at}kau.edu.sa
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background There has been considerable interest in statins due to their pleiotropic effects beyond their lipid-lowering properties. Many of these pleiotropic effects are predominantly ascribed to their capacity to inhibit the isoprenylation of Rho small guanosine triphosphatases (Rho GTPases). We aimed to genetically investigate the role of lipids and statin interventions on multiple sclerosis (MS) risk and severity.

Method We employed two-sample Mendelian randomization (MR) to: (1) investigate the causal role of lipids (high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG)) levels in MS risk and severity, (2) genetically mimic both cholesterol-dependent (via low-density lipoprotein cholesterol (LDL-C) and cholesterol biosynthesis pathway) and cholesterol-independent (via Rho GTPases) effects of statins on MS risk and MS severity.

Results The results of MR using the inverse variance weighted method show that lifelong higher HDL-C (OR 1.14 (95% CI 1.04 to1.26), p-value 7.94E-03) increase MS risk, but LDL-C and TG were not. MR results also show that genetically predicted RAC2 (OR 0.86 (95% CI 0.78 to 0.95), p-value 3.80E-03) is implicated causally in reducing MS risk. Furthermore, we found no evidence for the causal role of lipids and genetically mimicked statins on MS severity. There is no evidence of reverse causation between MS risk and lipids.

Conclusions Evidence from this study suggests that HDL-C is a risk factor for MS development. The MR findings suggest that RAC2 (a member of Rho GTPases) is a potent genetic modifier of MS risk. Since RAC2 has been reported to mediate some of the pleiotropic effects of statins, we suggest that statins reduce MS risk via a RAC2-related mechanism(s) (i.e., cholesterol-independent pathway).

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The author(s) disclosed receipt of the following financial support for the research: M.M.A. is funded by the Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.C.F received additional support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. C.S.S. is funded by Rosetrees Trust, John Black Charitable Foundation and the University College London MBPhD Programme. A.F.S is supported by BHF grant PG/18/503383, and acknowledges support by grant R01 LM010098 from the National Institutes of Health (United States). D.A.K. is supported by an MBPhD Award from the International Journal of Experimental Pathology. R.C. is funded by Eisai, on the Wolfson-Eisai Neurodegeneration University College London PhD programme. N.W.W. is a National Institute for Health Research senior investigator. N.W.W. receives support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All individuals involved in the multiple sclerosis risk and multiple sclerosis severity studies (cases and controls) gave valid informed consent in accordance with approval from the relevant local Ethical Committees or Institutional Review Boards (IRBs). These data are publicly available upon request.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The GWAS summary data used in this article are available at the URLs as follows: Lipid fractions (GLGC) http://csg.sph.umich.edu/willer/public/lipids2013/ ; whole blood cis-eQTL (eQTLgen consortium) https://www.eqtlgen.org/cis-eqtls.html ; whole blood cis-seQTL (GTx consortium) https://www.gtexportal.org/home/datasets ;HDL-C (Neale Lab UK Biobank GWAS) https://docs.google.com/spreadsheets/d/1kvPoupSzsSFBNSztMzl04xMoSC3Kcx3CrjVf4yBmESU/edit#gid=178908679 ; MS risk (discovery) https://imsgc.net/?page_id=31 ; MS severity data is available upon request to the corresponding author of the original publication (Sawcer et al., 2011), Professor Jacob McCauley.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted August 05, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study
Mona M. Almramhi, Chris Finan, Catherine S. Storm, Amand F. Schmidt, Demis A. Kia, Rachel Coneys, Sandesh Chopade, Aroon D. Hingorani, Nicholas W. Wood
medRxiv 2022.08.01.22277781; doi: https://doi.org/10.1101/2022.08.01.22277781
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study
Mona M. Almramhi, Chris Finan, Catherine S. Storm, Amand F. Schmidt, Demis A. Kia, Rachel Coneys, Sandesh Chopade, Aroon D. Hingorani, Nicholas W. Wood
medRxiv 2022.08.01.22277781; doi: https://doi.org/10.1101/2022.08.01.22277781

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (433)
  • Allergy and Immunology (758)
  • Anesthesia (222)
  • Cardiovascular Medicine (3308)
  • Dentistry and Oral Medicine (365)
  • Dermatology (282)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1174)
  • Epidemiology (13391)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5168)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3282)
  • Health Policy (1144)
  • Health Systems and Quality Improvement (1197)
  • Hematology (432)
  • HIV/AIDS (1021)
  • Infectious Diseases (except HIV/AIDS) (14647)
  • Intensive Care and Critical Care Medicine (914)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (525)
  • Neurology (4941)
  • Nursing (262)
  • Nutrition (733)
  • Obstetrics and Gynecology (887)
  • Occupational and Environmental Health (796)
  • Oncology (2526)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (546)
  • Pediatrics (1304)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4221)
  • Public and Global Health (7522)
  • Radiology and Imaging (1710)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (981)
  • Rheumatology (480)
  • Sexual and Reproductive Health (499)
  • Sports Medicine (425)
  • Surgery (550)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (206)